Dublin, June 09, 2022 (GLOBE NEWSWIRE) -- The "Macular Degeneration Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
The global macular degeneration treatment market reached a value of US$ 8.33 Billion in 2021. Looking forward, the publisher expects the market to reach a value of US$ 12.5 Billion by 2027 exhibiting a CAGR of 6.70% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Macular degeneration is a neurodegenerative ocular disorder that affects the eyes and causes blurred or loss of vision in the center of the visual field. It is characterized by blind spots in the field of vision, visual distortions and inability to see in low light conditions.
Some of the commonly used therapeutic techniques for macular degeneration includes anti-angiogenic drugs, photodynamic laser therapies, contact lenses and transitional lenses. Laser therapy involves the insertion of specialized contact lenses into the affected are of the eye, which are sealed by lasers along with the blood vessels.
Anti-angiogenic drugs are used for preventing blockages and leakages in the blood vessels. Timely treatment of macular degeneration treatment can aid in enhancing vision and minimizing the risks of developing chronic blindness.
Macular Degeneration Treatment Market Trends:
The increasing incidences of age-related macular degeneration and obesity among the masses is one of the key factors driving the market growth. The changing dietary patterns and the rising adoption of sedentary lifestyles is leading to the development of macular degeneration.
Additionally, the increasing utilization of smartphones, laptops and television, which is leading to prolonged and excessive screen time is also impacting the occurrence of the disorder. Moreover, the development of retinal gene therapies that involves the injection of adeno-associated virus (AAV) into the body for preventing the development of abnormal blood vessels is providing a thrust to the market growth.
In line with this, significant improvements in the healthcare infrastructure is positively impacting the market growth. Other factors, including extensive research and development (R&D) activities for the development of innovative and effective drugs, along with the implementation of various government initiatives for promoting public health, are anticipated to drive the market toward growth.
Key Market Segmentation:
The publisher provides an analysis of the key trends in each sub-segment of the global macular degeneration treatment market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on type, stage of disease, route of administration and end user.
Breakup by Type:
- Dry Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
Breakup by Stage of Disease:
- Early Stage
- Intermediate Stage
- Late Stage
Breakup by Route of Administration:
- Intravenous Route
- Intravitreal Route
Breakup by End User:
- Hospitals
- Ambulatory Surgical Center
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Aerie Pharmaceuticals Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, Iveric Bio Inc., Novartis AG, Panoptica, Pfizer Inc., Phio Pharmaceuticals, Regeneron Pharmaceuticals Inc., Regenxbio Inc. and Santen Pharmaceutical Co. Ltd.
Key Questions Answered in This Report:
- How has the global macular degeneration treatment market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global macular degeneration treatment market?
- What are the key regional markets?
- What is the breakup of the market based on the type?
- What is the breakup of the market based on the stage of disease?
- What is the breakup of the market based on the route of administration?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global macular degeneration treatment market and who are the key players?
- What is the degree of competition in the industry?
Key Topics Covered:
1 Preface
2 Scope and Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Macular Degeneration Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Type
6.1 Dry Age-related Macular Degeneration
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Wet Age-related Macular Degeneration
6.2.1 Market Trends
6.2.2 Market Forecast
7 Market Breakup by Stage of Disease
7.1 Early Stage
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Intermediate Stage
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Late Stage
7.3.1 Market Trends
7.3.2 Market Forecast
8 Market Breakup by Route of Administration
8.1 Intravenous Route
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Intravitreal Route
8.2.1 Market Trends
8.2.2 Market Forecast
9 Market Breakup by End User
9.1 Hospitals
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Ambulatory Surgical Center
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Others
9.3.1 Market Trends
9.3.2 Market Forecast
10 Market Breakup by Region
11 SWOT Analysis
12 Value Chain Analysis
13 Porters Five Forces Analysis
14 Price Analysis
15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Aerie Pharmaceuticals Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.2 Bausch Health Companies Inc.
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 Bayer AG
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 F. Hoffmann-La Roche Ltd
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 Financials
15.3.5 Iveric Bio Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.6 Novartis AG
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Panoptica
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.8 Pfizer Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Phio Pharmaceuticals
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.10 Regeneron Pharmaceuticals Inc.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Regenxbio Inc.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis
15.3.12 Santen Pharmaceutical Co. Ltd.
15.3.12.1 Company Overview
15.3.12.2 Product Portfolio
15.3.12.3 Financials
15.3.12.4 SWOT Analysis
For more information about this report visit https://www.researchandmarkets.com/r/6ne6q7
Attachment
